[ZSE-DUO - dual guidance structure at the centre for rare diseases].

Inn Med (Heidelb)

Zentrum für Seltene Erkrankungen - Referenzzentrum Nordbayern (ZESE), Universitätsklinikum Würzburg, Würzburg, Deutschland.

Published: July 2022

Background: Patients with an unclear diagnosis and suspected rare disease pose special challenges to physicians, among others.

Aim Of The Study (research Question): The ZSE-DUO project aims to establish whether patient care under the joint supervision of a somatic expert and a mental health expert can improve diagnostic efficacy and precision, as well as shorten the time to diagnosis.

Material And Methods: ZSE-DUO has successfully recruited more than 1000 patients at eleven national centres for rare diseases in a control and an intervention group. The findings are being analysed by three evaluating institutions.

Results And Discussion: The study is currently in its final phase. The results will be published in further papers.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00108-022-01350-8DOI Listing

Publication Analysis

Top Keywords

[zse-duo - dual
4
dual guidance
4
guidance structure
4
structure centre
4
centre rare
4
rare diseases]
4
diseases] background
4
background patients
4
patients unclear
4
unclear diagnosis
4

Similar Publications

Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with limited treatment options and a poor prognosis. The critical role of epigenetic alterations such as changes in DNA methylation, histones modifications, and chromatin remodeling, in pancreatic tumors progression is becoming increasingly recognized. Moreover, in PDAC these aberrant epigenetic mechanisms can also limit therapy efficacy.

View Article and Find Full Text PDF

Early-onset (EOCC) and late-onset cervical cancers (LOCC) represent two clinically distinct subtypes, each defined by unique clinical manifestations and therapeutic responses. However, their immunological profiles remain poorly explored. Herein, we analyzed single-cell transcriptomic data from 4 EOCC and 4 LOCC samples to compare their immune architectures.

View Article and Find Full Text PDF

Exploring the barriers to cervical screening and perspectives on new self-sampling methods amongst under-served groups.

BMC Health Serv Res

January 2025

NIHR Greater Manchester Patient Safety Research Collaboration, Centre for Primary Care & Health Services Research, School of Health Sciences, Faculty of Biology, Medicine & Health, The University of Manchester, Greater Manchester, England, UK.

Background: Cervical screening rates have fallen in recent years in the UK, representing a health inequity for some under-served groups. Self-sampling alternatives to cervical screening may be useful where certain barriers prohibit access to routine cervical screening. However, there is limited evidence on whether self-sampling methods address known barriers to cervical screening and subsequently increase uptake amongst under-screened groups.

View Article and Find Full Text PDF

Background: Head and neck squamous cell carcinoma (HNSCC), a highly invasive malignancy with a poor prognosis, is one of the most common cancers globally. Circular RNAs (circRNAs) have become key regulators of human malignancies, but further studies are necessary to fully understand their functions and possible causes in HNSCC.

Methods: CircCCT2 expression levels in HNSCC tissues and cells were measured via qPCR.

View Article and Find Full Text PDF

Regulatory role of lnc-MAP3K13-3:1 on miR-6894-3p and SHROOM2 in modulating cellular dynamics in hepatocellular carcinoma.

BMC Cancer

January 2025

Jiangxi Provincial Key Laboratory of Child Development and Genetics, Jiangxi Provincial Children's Hospital, No. 122 of YangMing Road, DongHu District, NanChang, 330006, China.

Background: Hepatocellular carcinoma (HCC) is a prevalent primary liver malignancy and a leading cause of cancer-related mortality worldwide. Despite advancements in therapeutic strategies, the 5-year survival rate for individuals undergoing curative resection remains between 10% and 15%. Consequently, identifying molecular targets that specifically inhibit the proliferation and metastasis of HCC cells is critical for improving treatment outcomes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!